u/Avish_Golakiya · 24h ago31 prior · 63% at 3mo
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
HUMA is presenting Phase 3 data at Kidney Week this week for a dialysis-access therapy already on market with accelerating hospital adoption. Despite a low share price and tight runway, the near-term data readout and commercial momentum provide a near-term catalyst.
At post $0.41Now $0.40-2.4% since posted13m ago